U.S. Markets open in 5 hrs 57 mins

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
31.62-1.65 (-4.96%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close33.27
Open33.25
Bid0.00 x 900
Ask0.00 x 1000
Day's Range28.43 - 33.90
52 Week Range2.94 - 60.00
Volume197,137
Avg. Volume84,241
Market Cap138.456M
Beta (5Y Monthly)7.47
PE Ratio (TTM)N/A
EPS (TTM)-5.84
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.67
  • ACCESSWIRE

    Aptevo Confirms Receipt of Nominations and Proposal Notice

    Stockholders Are Not Required to Take Any Action at this TimeSEATTLE, WA / ACCESSWIRE / February 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today confirmed that it has received a notice from Tang Capital Partners, LP ("TCP") that TCP intends to nominate two candidates to stand for election to the Board of Directors and submit an advisory stockholder proposal at the Company's 2021 Annual Meeting of Stockholders.

  • ACCESSWIRE

    Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

    SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.

  • Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
    Zacks

    Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why

    Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).